| Title |
Cost-effectiveness of candesartan versus losartan in the primary preventive treatment of hypertension
|
|---|---|
| Published in |
ClinicoEconomics and Outcomes Research: CEOR, November 2012
|
| DOI | 10.2147/ceor.s35824 |
| Pubmed ID | |
| Authors |
Ola Granström, Lars-Åke Levin, Martin Henriksson |
| Abstract |
Although angiotensin receptor blockers have different receptor binding properties, no comparative randomized studies with cardiovascular event endpoints have been performed for this class of drugs. The aim of this study was to assess the long-term cost-effectiveness of candesartan (Atacand(®)) versus generic losartan in the primary preventive treatment of hypertension. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 1 | 4% |
| Unknown | 27 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 9 | 32% |
| Researcher | 7 | 25% |
| Student > Ph. D. Student | 4 | 14% |
| Other | 2 | 7% |
| Student > Bachelor | 2 | 7% |
| Other | 2 | 7% |
| Unknown | 2 | 7% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 43% |
| Economics, Econometrics and Finance | 4 | 14% |
| Social Sciences | 3 | 11% |
| Agricultural and Biological Sciences | 2 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 7% |
| Other | 1 | 4% |
| Unknown | 4 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 November 2012.
All research outputs
#20,823,121
of 25,584,565 outputs
Outputs from ClinicoEconomics and Outcomes Research: CEOR
#429
of 514 outputs
Outputs of similar age
#158,651
of 202,619 outputs
Outputs of similar age from ClinicoEconomics and Outcomes Research: CEOR
#6
of 8 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 514 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.1. This one is in the 8th percentile – i.e., 8% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 202,619 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 10th percentile – i.e., 10% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.